外周血管介入中使用二氧化碳血管造影与晚期慢性肾脏病患者心脏及肾脏并发症减少相关
基于2010至2021年血管质量倡议外周血管介入数据集,纳入估算肾小球滤过率<45 ml/min/1.73 m2的晚期慢性肾脏病患者,经倾向性匹配后每组4472例,CO2血管造影组对比剂用量减少50%,造影后急性肾损伤和心脏并发症发生率均更低,技术失败及截肢无显著差异。
要点
- 晚期慢性肾脏病患者外周血管介入中仅22%使用CO2血管造影。
- 匹配后CO2组对比剂用量32±33 mL vs 非CO2组65±48 mL,减少50%。
- CO2组造影后急性肾损伤3.9% vs 4.8%,心脏并发症2.1% vs 2.9%。
核心结论
- CO2血管造影减少外周血管介入中碘对比剂用量,与心脏并发症和造影后急性肾损伤减少相关。
- CO2血管造影使用不足,作者认为晚期慢性肾脏病需血管内治疗的患者应考虑使用。
研究设计与样本
- 回顾性分析血管质量倡议外周血管介入数据集2010至2021年数据。
- 纳入估算肾小球滤过率<45 ml/min/1.73 m2、因外周动脉疾病治疗的晚期慢性肾脏病患者。
- 采用倾向性匹配和多因素 logistic 回归比较使用与未使用CO2血管造影患者的结局。
主要发现
- 共20706例外周血管介入,仅22%使用CO2血管造影。
- 倾向性匹配后每组4472例,CO2组对比剂用量32±33 mL vs 非CO2组65±48 mL(P < .01),减少50%。
- CO2组造影后急性肾损伤3.9% vs 非CO2组4.8%(P = .03)。
- CO2组心脏并发症2.1% vs 非CO2组2.9%(P = .03)。
- 技术失败及大/小截肢无显著差异。
关键数值与推荐
- 低对比剂用量(CKD3期≤50 mL、CKD4期≤20 mL、CKD5期≤9 mL)与造影后急性肾损伤风险降低相关(风险比0.59;P < .01)。
临床怎么用
- 作者认为,晚期慢性肾脏病需血管内治疗的患者应考虑使用CO2血管造影。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with chronic kidney disease (CKD) who undergo peripheral vascular interventions (PVI) with iodinated contrast are at higher risk of post-contrast acute kidney injury (PC-AKI). Carbon dioxide (CO2) angiography can reduce iodinated contrast volume usage in this patient population, but its impact on PC-AKI has not been studied. We hypothesize that CO2 angiography is associated with a decrease in PC-AKI in patients with advanced CKD. METHODS: The Vascular Quality Initiative PVI dataset from 2010 to 2021 was reviewed. Only patients with advanced CKD (estimated glomular filtration rate <45 ml/min/1.73 m2) treated for peripheral arterial disease were included. Propensity matching and multivariate logistic regression based on demographics, comorbidities, CKD stage, and indications were used to compare the outcomes of patients treated with and without CO2. RESULTS: There were 20,706 PVIs performed in patients with advanced CKD, and only 22% utilized CO2 angiography. Compared with patients treated without CO2, patients who underwent CO2 angiography were younger and less likely to be women or White, and more likely to have poor renal function, diabetes, cardiac comorbidities, and present with tissue loss. Propensity matching yielded well-matched groups with 4472 patients in each group. The procedural details after matching demonstrated 50% reduction in the volume of contrast used (32±33 vs 65±48 mL; P < .01). PVI with CO2 angiography was associated with lower rates of PC-AKI (3.9% vs 4.8%; P = .03) and cardiac complications (2.1% vs 2.9%; P = .03) without a significant difference in technical failure or major/minor amputations. Low contrast volumes (≤50 mL for CKD3, ≤20 mL for CKD4, and ≤9 mL for CKD5) are associated with reduced risk of PC-AKI (hazard ratio, 0.59; P < .01). CONCLUSIONS: CO2 angiography reduces iodinated contrast volume usage during PVI and is associated with decreased cardiac complications and PC-AKI. CO2 angiography is underutilized and should be considered for patients with advanced CKD who require endovascular therapy.
引用
- Lee SR, Ali S, Cardella J, et al. Carbon dioxide angiography during peripheral vascular interventions is associated with decreased cardiac and renal complications in patients with chronic kidney disease. J Vasc Surg. 2023. PMID: 36948278. doi:10.1016/j.jvs.2023.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。